Education
About Us
Working with TipRanks
Follow Us
Strata Skin Sciences (SSKN)
:SSKN
SSKN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.38 - $3.86
Previous CloseN/A
Volume547.00
Average Volume (3M)6.04M
Market Cap
$10.85M
Enterprise Value$19.94M
Total Cash (Recent Filing)$5.97M
Total Debt (Recent Filing)$1.08M
Price to Earnings (P/E)―
Beta-0.19
Next Earnings
Nov 18, 2025EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding5,268,708
10 Day Avg. Volume12,231,470
30 Day Avg. Volume6,041,337
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.84
Enterprise Value/Revenue0.61
Enterprise Value/Gross Profit1.05
Enterprise Value/Ebitda-2.72
Forecast
1Y Price Target
$4.00Price Target Upside93.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Market PotentialSignificant opportunities in the dermatology market, with the potential for growth in the global treatment market expected to reach $44B by 2031.
Revenue GrowthAll clinics who have gone through the company’s consulting process have shown higher year-over-year revenue.
Strategic PlanDr. Dolev Rafaeli was reappointed as CEO and has implemented a strategic turnaround plan focused on direct-to-consumer marketing to drive patient volume.
Bears Say
International Revenue PressureThe 2Q25 revenue miss was primarily due to international weakness related to tariffs which could continue to pressure the topline through the remainder of 2025.
Strata Skin Sciences News
SSKN FAQ
What was Strata Skin Sciences’s price range in the past 12 months?
Strata Skin Sciences lowest stock price was $1.38 and its highest was $3.86 in the past 12 months.
What is Strata Skin Sciences’s market cap?
Strata Skin Sciences’s market cap is $10.85M.
When is Strata Skin Sciences’s upcoming earnings report date?
Strata Skin Sciences’s upcoming earnings report date is Nov 18, 2025 which is in 46 days.
How were Strata Skin Sciences’s earnings last quarter?
Strata Skin Sciences released its earnings results on Aug 13, 2025. The company reported -$0.186 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.102.
Is Strata Skin Sciences overvalued?
According to Wall Street analysts Strata Skin Sciences’s price is currently Undervalued.
Does Strata Skin Sciences pay dividends?
Strata Skin Sciences does not currently pay dividends.
What is Strata Skin Sciences’s EPS estimate?
Strata Skin Sciences’s EPS estimate is -0.53.
How many shares outstanding does Strata Skin Sciences have?
Strata Skin Sciences has 5,268,708 shares outstanding.
What happened to Strata Skin Sciences’s price movement after its last earnings report?
Strata Skin Sciences reported an EPS of -$0.186 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went down -3.723%.
Which hedge fund is a major shareholder of Strata Skin Sciences?
Currently, no hedge funds are holding shares in SSKN
Company Description
Strata Skin Sciences
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC and Pharos excimer lasers, VTRAC lamp systems, and TheraClear treatment systems that are used for the treatment of psoriasis, vitiligo, acne, and other skin conditions. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
SSKN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook. While there were significant positive developments like the expansion of CPT codes and increased device placements, the company faced substantial challenges, including revenue declines and international market disruptions. Despite efforts to expand the market and improve reimbursement rates, financial performance was impacted by legal expenses and decreased international and equipment revenues.View all SSKN earnings summariesSSKN Stock 12 Month Forecast
Average Price Target
$4.00
▲(93.24% Upside)
Technical Analysis
Ownership Overview
3.10% Insiders
2.13% Mutual Funds
18.41% Other Institutional Investors
75.50% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---